KR100827350B1 - Herbal medicine composition for descending blood sugar - Google Patents
Herbal medicine composition for descending blood sugar Download PDFInfo
- Publication number
- KR100827350B1 KR100827350B1 KR1020060133561A KR20060133561A KR100827350B1 KR 100827350 B1 KR100827350 B1 KR 100827350B1 KR 1020060133561 A KR1020060133561 A KR 1020060133561A KR 20060133561 A KR20060133561 A KR 20060133561A KR 100827350 B1 KR100827350 B1 KR 100827350B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- blood sugar
- herbal medicine
- herbal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 103
- 239000008280 blood Substances 0.000 title claims abstract description 93
- 210000004369 blood Anatomy 0.000 title claims abstract description 93
- 241000411851 herbal medicine Species 0.000 title claims abstract description 87
- 235000000346 sugar Nutrition 0.000 title claims abstract description 74
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 34
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 21
- 235000010755 mineral Nutrition 0.000 claims abstract description 21
- 239000011707 mineral Substances 0.000 claims abstract description 21
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract description 10
- 229910000365 copper sulfate Inorganic materials 0.000 claims abstract description 6
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims abstract description 6
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims abstract description 6
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 6
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 6
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims abstract description 6
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229910000368 zinc sulfate Inorganic materials 0.000 claims abstract description 6
- 229960001763 zinc sulfate Drugs 0.000 claims abstract description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 5
- 229940099596 manganese sulfate Drugs 0.000 claims abstract description 5
- 239000011702 manganese sulphate Substances 0.000 claims abstract description 5
- 235000007079 manganese sulphate Nutrition 0.000 claims abstract description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims abstract description 5
- 229960000355 copper sulfate Drugs 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 13
- 230000001882 diuretic effect Effects 0.000 claims description 13
- 239000011593 sulfur Substances 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 230000036737 immune function Effects 0.000 claims description 12
- 235000013372 meat Nutrition 0.000 claims description 12
- 239000003381 stabilizer Substances 0.000 claims description 12
- 244000025254 Cannabis sativa Species 0.000 claims description 11
- 240000001008 Dimocarpus longan Species 0.000 claims description 11
- 235000000235 Euphoria longan Nutrition 0.000 claims description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 11
- 239000010865 sewage Substances 0.000 claims description 11
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 10
- 241000209020 Cornus Species 0.000 claims description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 10
- 235000017803 cinnamon Nutrition 0.000 claims description 10
- 210000004207 dermis Anatomy 0.000 claims description 10
- 229940010454 licorice Drugs 0.000 claims description 10
- 239000003223 protective agent Substances 0.000 claims description 10
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 9
- 240000000513 Santalum album Species 0.000 claims description 9
- 235000008632 Santalum album Nutrition 0.000 claims description 9
- 239000012676 herbal extract Substances 0.000 claims description 9
- 229910052573 porcelain Inorganic materials 0.000 claims description 9
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 8
- 244000170916 Paeonia officinalis Species 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 244000144725 Amygdalus communis Species 0.000 claims description 7
- 240000002045 Guettarda speciosa Species 0.000 claims description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- 235000020224 almond Nutrition 0.000 claims description 7
- 230000001079 digestive effect Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 230000029087 digestion Effects 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 3
- 235000008216 herbs Nutrition 0.000 claims description 3
- 235000002566 Capsicum Nutrition 0.000 claims description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- 239000006002 Pepper Substances 0.000 claims description 2
- 235000016761 Piper aduncum Nutrition 0.000 claims description 2
- 240000003889 Piper guineense Species 0.000 claims description 2
- 235000017804 Piper guineense Nutrition 0.000 claims description 2
- 235000008184 Piper nigrum Nutrition 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 235000011437 Amygdalus communis Nutrition 0.000 claims 1
- 240000008067 Cucumis sativus Species 0.000 claims 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 15
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 5
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract description 3
- 241000202722 Bupleurum falcatum Species 0.000 abstract 1
- 241001071917 Lithospermum Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 239000008103 glucose Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000004190 glucose uptake Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000003472 antidiabetic agent Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 240000008866 Ziziphus nummularia Species 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940126904 hypoglycaemic agent Drugs 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 6
- 235000013312 flour Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 230000010030 glucose lowering effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000000052 vinegar Substances 0.000 description 5
- 235000021419 vinegar Nutrition 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000002020 sage Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 229960005371 tolbutamide Drugs 0.000 description 3
- 235000015192 vegetable juice Nutrition 0.000 description 3
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 235000003880 Calendula Nutrition 0.000 description 2
- 240000001432 Calendula officinalis Species 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 235000003228 Lactuca sativa Nutrition 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000009536 samultang Substances 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- -1 that is Substances 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- MYGCFWRBKKQKCG-GBWOLBBFSA-N (z,2r,3s,4r)-hex-5-ene-1,2,3,4,6-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)\C=C/O MYGCFWRBKKQKCG-GBWOLBBFSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010037597 Pyelonephritis acute Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 201000001555 acute pyelonephritis Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001929 anti-hepatotoxic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- ZEASOXUPPLSUSE-UHFFFAOYSA-N butanedioic acid;sulfane Chemical compound S.OC(=O)CCC(O)=O ZEASOXUPPLSUSE-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
본 발명은 혈당강하 생약 조성물에 관한 것이다.The present invention relates to a hypoglycemic herbal composition.
생활습관과 관련된 질환의 대표적인 예로서 일컬어지는 당뇨병은 현저한 고혈당이나 케토산증(ketoacidosis)에 기인하는 급성 증상 또는 지속적인 고혈당 상태나 내당력 저하에 기인하는 각종 만성적·전신적인 대사 이상을 초래하는 질환이다. 당뇨병의 발병 요인에는 유전적인 요인과 식생활이나 운동량 등의 환경에 의한 요인이 있으며, 이들 양자가 서로 영향을 미치기 때문에 당뇨병의 발병 형태, 질병의 진행이 다양하며, 최근 세계적인 평균수명의 연장과 식생활의 다양한 변화로 그 발생빈도가 꾸준히 증가하여, 매년에 50만 명씩 증가하고 있으며, 현재 10명당 1명씩으로 매년 증가하고 있는 추세이다.Diabetes, which is a representative example of a lifestyle-related disease, is a disease that causes acute symptoms due to significant hyperglycemia or ketoacidosis or various chronic and systemic metabolic abnormalities due to persistent hyperglycemic conditions or decreased glucose tolerance. There are genetic factors and factors such as genetic factors and the environment such as diet and exercise, and because they affect each other, various forms of diabetes mellitus and disease progression. The frequency of occurrence is steadily increasing due to various changes, and the number of people is increasing by 500,000 every year, and it is increasing every year by 1 person per 10 people.
당뇨병은 인슐린 의존성 당뇨병(Insulin Dependent Diabetes Mellitus; 이 하, IDDM; 타입 I 당뇨병)과 인슐린 비의존성 당뇨병(NonInsulin Dependent Diabetes Mellitus; 이하, NIDDM; 타입 II 당뇨병)으로 구분된다. IDDM은 유전적 인자에 의하여 발병하거나, 바이러스의 감염, 자가면역의 감염으로 췌장의 β-세포를 파괴하며 발생하는 것으로 급성적이며 30대 이하의 젊은 사람에게 많이 나타난다. 대부분 마른 체형이며 체중은 감소하고 인슐린의 양이 절대적으로 부족하다. NIDDM은 비만, 스트레스, 식사의 잘못 또는 인슐린과 길항(拮抗)하는 약물 등에 의해 발병된다. 만성적이고 성인들에게 많이 나타나며 가장 흔한 형태의 당뇨병으로 췌장의 베타세포에는 이상이 없고, 비만이나 세포내의 인슐린 수용체의 결핍에 의해 발병한다. 이 유형에도 어느 정도 유전적 소인이 작용한다는 것이 역학적으로 인정되고 있으나, 식사의 잘못, 운동부족, 스트레스, 중금속 오염, 임신, 비만, 내분비계통 장애 및 약물의 부작용 등 후천적 요인이 깊다.Diabetes is divided into Insulin Dependent Diabetes Mellitus (hereinafter referred to as IDDM; Type I Diabetes) and Insulin Dependent Diabetes Mellitus (hereinafter referred to as NIDDM; Type II Diabetes). IDDM is caused by genetic factors, viral infections, and autoimmune infections that destroy pancreatic β-cells. It is acute and occurs in young people under 30 years of age. Most are skinny, lose weight, and are absolutely deficient in insulin. NIDDM is caused by obesity, stress, eating faults, or drugs that antagonize insulin. Chronic, common in adults, and the most common form of diabetes, the pancreatic beta cells have no abnormality, and are caused by obesity or lack of intracellular insulin receptors. It is epidemiologically recognized that there is some degree of genetic predisposition to this type, but there are a number of acquired factors, including eating wrong, lack of exercise, stress, heavy metal contamination, pregnancy, obesity, endocrine disorders, and side effects of drugs.
당뇨병 치료제로는 IDDM의 경우 현재까지는 인슐린만이 가장 이상적이고 효과적인 약물로 선택되어 사용되어지고 있으나 그 지속시간이 짧고 영구적으로는 작용을 나타내지 못하며 주사제로만 사용해야하는 단점이 있으며, 더구나 인슐린 호르몬 제재는 혈당이 정상인 경우라도 투여하면 혈당이 떨어지게 되어 저혈당 증상이 나타나는데 심한 경우 치료하지 않을 경우 경련, 무의식, 뇌 손상을 유발하여 사망에 이를 수도 있다. In the case of IDDM, only insulin has been selected as the most ideal and effective drug to date. However, its duration is short, it does not show permanent action, and it has the disadvantage of being used only as an injection. Even if this is normal, blood sugar drops and symptoms of hypoglycemia appear. In severe cases, if not treated, convulsions, unconsciousness, and brain damage may result in death.
또한, 당뇨가 있는 환자들은 혈액이 혼탁하고 여러 가지 부조화에 의하여 동맥경화나 심장질환, 신부전증 등 다양한 순환기의 합병증을 유발하기도 하며 심할 경우, 신체 말단부위에 혈액 공급이 원활히 이루어지지 않아, 말단 조직이 괴사될 수도 있다.In addition, patients with diabetes may have turbid blood and various incompatibilities that cause complications of various circulatory organs such as arteriosclerosis, heart disease, renal failure, and in severe cases, blood supply to the distal parts of the body is not smooth, resulting in necrosis of terminal tissues. May be
NIDDM의 경우 인슐린과 더불어 혈당 강하제를 사용하는데 현재까지 사용되고 있는 대표적 경구용 혈당 강하제로는 톨부타미드(tolbutamide), 클로르프로파미드, 글리벤클라미드 등의 설폰요산계(sulphonylurea) 및 메트포르민, 부포르민 등의 비구아니드(biguanid)계 약물이 있다. 그러나 설폰요산계 약물은 간독성 및 저혈당을 야기하며, 비구아니드계 약물도 역시 산증(lactic acidosis)을 유발하는 부작용을 가지고 있다. 특히 상기의 당뇨병 치료제 중에서, 혈당 강하를 조절함으로써 당뇨를 치료할 목적으로 사용되는 가장 대표적인 것이 톨부타미드인데 톨부타미드를 당뇨병 치료제로 사용하는 경우 췌장암, 통증, 혈흔 등의 우려가 있고, 과잉 투여하게 되면 환자의 건강상태가 좋지 않을 경우 생명에 치명적 위험을 가할 수 있는 맹점이 있으며, 혈당강하 효과가 빨리 나타나지만, 효과가 지속적이지 못한 문제점이 있다. 이에, 부작용이 적으면서도, 혈당 강하 효과가 우수한 한약 조성물에 대한 연구가 활발히 진행되고 있다.In the case of NIDDM, in addition to insulin, a blood glucose lowering agent is used. Representative oral blood glucose lowering agents used to date include sulfonylurea, metformin, butol, such as tolbutamide, chlorpropamide, and glybenclamide. Biguanid-based drugs such as formin. However, sulfonic uric acid-based drugs cause hepatotoxicity and hypoglycemia, and biguanide-based drugs also have side effects that cause lactic acidosis. Particularly, among the above-mentioned diabetic drugs, tolbutamide is used for the purpose of treating diabetes by controlling blood sugar drop. However, when tolbutamide is used as a diabetic drug, pancreatic cancer, pain, blood stains, etc., may be overdosed. If there is a blind spot that can pose a fatal risk to life when the health of the patient is not good, blood glucose lowering effect appears quickly, but the effect is not persistent. Accordingly, studies on herbal compositions excellent in blood sugar lowering effects while having fewer side effects are being actively conducted.
종래에, 생약 조성물을 이용한 혈당 강하용 조성물로는 대한민국 등록특허 제542809호에 오미자 16 내지 24 중량부, 연자육 32 내지 48 중량부, 하수오 32내지 48 중량부, 인삼 32 내지 48 중량부, 구기자 32 내지 48 중량부, 산약 32 내지 48 중량부, 백출 32 내지 48 중량부, 맥문동 32 내지 48 중량부, 산수유 32 내지 48 중량부, 녹용 8 내지 12 중량부, 백모근 64 내지 96 중량부, 백복령 16 내지 24 중량부, 및 복분자 16 내지 24 중량부를 포함하는 혈당 강하용 생약조성물 ,및 이러한 생약혼합물을 90 내지 100 ℃까지 가열하고, 2 내지 3시간 동안 추출하여 생약조성물을 제조하는 혈당 강하용 생약 조성물, 이의 제조방법 및 이를 포함하는 약학제재에 대해서 기재되어 있다. Conventionally, as a composition for lowering blood sugar using the herbal composition, S. Korean Patent No. 542809 discloses 16 to 24 parts by weight, 32 to 48 parts by weight of lotus root, 32 to 48 parts by weight of sewage, 32 to 48 parts by weight of ginseng 32 To 48 parts by weight, about 32 to 48 parts by weight, 32 to 48 parts by weight, 32 to 48 parts by weight of Macmundong, 32 to 48 parts by weight of cornus oil, 8 to 12 parts by weight of deer antler, 64 to 96 parts by weight of white hair root, 16 to 100 bags Herbal composition for lowering blood sugar, comprising 24 parts by weight, and 16 to 24 parts by weight of bokbunja, and a herbal composition for lowering blood sugar, which is heated to 90 to 100 ° C. and extracted for 2 to 3 hours to produce a herbal composition, It describes a preparation method thereof and a pharmaceutical preparation including the same.
또한, 대한민국 등록특허 제473529호에는 순기산 생약 복합제 즉, 후박, 대황 및 지실의 추출물을 유효성분으로 함유하고 항당뇨 활성이 우수한 당뇨병 예방 및 치료용 조성물에 대해서 기재되어 있다.In addition, the Republic of Korea Patent No. 473529 describes a composition for preventing and treating diabetes mellitus containing a pure herbal extract, that is, extracts of hubak, rhubarb and fruit as an active ingredient and excellent antidiabetic activity.
그러나, 상기 등록특허 제542809호는 혈당 강하용 생약 조성물의 제조에 있어서, 제조되는 주요 약제의 종류가 많아, 상기 약제의 주요 작용을 파악하기 힘들고, 상기 등록특허 제473529호는 순기산 생약 복합제는 이뇨작용이 주를 이루는 생약재로 구성되어 있는 단점을 가지고 있다.However, the registered patent No. 542809 has many kinds of main drugs to be prepared in the preparation of the herbal composition for lowering blood sugar, and it is difficult to grasp the main action of the drug. Diuretic effect is composed mainly of herbal medicines.
이에, 본 발명자는 태양인과 소양인에서 잘 발생하는 당뇨의 예방 및 치료법을 연구하던 중, 생약 중 냉성을 가지는 천화분, 지초, 상백피, 시호, 숙지황 등을 이용하여 제조되는 생약 조성물이 혈당 강화 효과를 보이는 것을 관찰하여, 본 발명을 완성하게 되었다. Thus, the present inventors while studying the prevention and treatment of diabetes well occurring in the sun people and Soyangin, herbal compositions prepared by using the cold water of herbal medicines, lichens, lettuce, baekhwi, sage, sulfur, etc. exhibits a blood sugar enhancing effect It was observed that this invention was completed.
본 발명의 목적은 혈당 강하 생약 조성물을 제공하는 데 있다.An object of the present invention is to provide a blood sugar lowering herbal composition.
상기 목적을 달성하기 위하여, 본 발명은 천화분, 지초, 상백피, 시호 및 숙지황의 혼합 추출물을 포함하여 이루어지는 혈당 강하 생약 조성물을 제공한다.In order to achieve the above object, the present invention provides a hypoglycemic herbal composition comprising a mixed extract of cheonhwabun, cheoncho, baekbaekpi, shiho and sukji sulfur.
또한, 본 발명은 이뇨 작용에 사용되는 생약재, 순환기를 돕기 위한 생약재, 소화흡수를 돕기 위하여 사용되는 생약재, 면역기능을 돕기 위하여 사용되는 생약재 및, 보호제 및 안정제로 사용되는 생약재의 추출물과, 이온성 미네랄을 더 포함하여 이루어지는 혈당 강하 생약 조성물을 제공한다.In addition, the present invention is an herbal medicine used for diuretic action, herbal medicine to help the circulatory system, herbal medicine used to help digestion absorption, herbal medicine used to help immune function, and extracts of herbal medicine used as a protective agent and stabilizer, and ionic It provides a blood sugar-lowering herbal composition further comprising a mineral.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 천화분, 지초, 상백피, 시호 및 숙지황의 혼합 추출물을 포함하여 이루어지는 혈당 강하 생약 조성물을 제공한다.The present invention provides a blood sugar lowering herbal composition comprising a mixed extract of cheonhwabun, cheonji, baekbaekpi, shiho and sukji sulfur.
동양의학의 사상의학에서 분석하여 보면 당뇨는 열성체질인 태양인과 소양인이 95%를 차지하며, 태음인이나 소음인을 조사하여 보면 거의 발병되지 않는데, 태양인은 생리적으로 겉열과 속열을 지니고 있으며 소양인은 속열이 많아 열성체질이라고 볼 수 있는 반면에, 냉성 체질인 태음인은 속에 찬 성질이 있으며 소음인은 속과 겉이 찬 성질이기 때문에 냉성 체질이라고 할 수 있다.In the ideology of oriental medicine, diabetics account for 95% of the heat constitution, sun people and yangyang people, and if you look at Taein people or noise people, it rarely occurs, but the sun people have physiological heat and heat, and Soyang people have heat. On the other hand, it can be said that the recessive constitution, while the cold constitution Taeumin has a cold nature inside and the noise person is a cold constitution because it is cold inside and outside nature.
당뇨는 신장과 방광기능이 약한 체질인 태양인과 소양인이 열성식품인 고추, 부추, 무우 등의 뿌리 식품에서 열을 발생하므로, 신장과 방광 기능이 떨어진 상태에서 이러한 뿌리 식품을 많이 섭취한 사람에서 열기운이 발생되고, 이때 면역기능 저하 되어 있다면, 소화기 계통 췌장에 열이 발생하게 되어 순간 혈당이 폭발적으로 나타난다고 한의학에서는 알려져 있다. 이러한 현상이 장기화될 경우, 당뇨병이 발병하게 될 수도 있다. 이에, 당뇨에 대한 한의학적 접근은 이러한 태양인과 소양인에게서 열기운을 낮춘다면, 혈당이 높아지는 것을 방지할 뿐만 아니라, 나아가 당뇨의 치료할 수 있다.Diabetes generates heat from root foods such as red peppers, leeks, and radishes, which are recessive foods such as Sunin and Soyangin, which have weak kidney and bladder functions. If luck occurs and the immune function is reduced, heat is generated in the pancreas of the digestive system, and it is known in Korean medicine that an instant blood glucose is exploded. If this phenomenon is prolonged, diabetes may develop. Therefore, the oriental medicine approach to diabetes can prevent the rise of blood sugar as well as the treatment of diabetes by lowering the heat cloud in these sun people and Soyang people.
한의학에서 냉성을 나타내는 한약재에는 천화분, 지초, 상백피, 시호, 숙지황 등이 있다.Herbal medicines that show coldness in oriental medicine include cheonhwabun, jicho, baekbaekpi, siho, sukjihwang and the like.
천화분은 하늘타리의 뿌리로서, 한의약에서는 주로 열로 인하여 진액이 손상되어 입 안이 마르며 혀가 건조하고 가슴 속이 답답하고 편안치 않아서 팔다리를 가만히 두지 못하는 증상 및 갈증을 많이 느끼는 소갈증에 널리 활용된다. 특히 입 안이 마르고 물과 음식을 많이 먹을 때에 유효하다. Cheonhwabun is the root of the sky feather, and is widely used in herbal medicines for thirst, which causes a lot of thirst due to heat damage, dry mouth, dry tongue, stuffy chest and uncomfortable feelings. It is especially effective when your mouth is dry and you eat a lot of water and food.
지초는 약성이 차다. 열을 내리고 독을 풀며 염증을 없애고 새살을 돋아나게 하는 작용이 뛰어나며, 갖가지 암, 변비, 간장병, 동맥경화, 여성의 냉증, 대하, 생리불순 등에 효과가 있으며 오래 복용하면 얼굴빛이 좋아진다고 한다. 지초를 중국에서는 암 치료약으로 쓰고 있다. 혀암, 위암, 갑상선암, 자궁암, 피부암에 지치와 까마중을 함께 달여 복용하게 하여 상당한 효과를 거두고 있다고 알려져 있다.The grass is weak. It is effective in lowering heat, releasing poison, removing inflammation, and boosting new life.It is effective in various cancers, constipation, liver disease, arteriosclerosis, women's coldness, treat, and menstrual irregularities. It is used as a medicine for cancer in China. Tongue cancer, stomach cancer, thyroid cancer, uterine cancer, skin cancer is known to have a significant effect by taking a combination of tired and crow weight.
상백피는 폐열로 인한 해수, 천식을 치료하며 이뇨 작용을 나타낸다. 급성신우염, 허약성 부종에 쓰이고 혈압강하 작용이 있으며 코피와 각혈에도 사용한다. 또한 유행성 간염 등에도 쓰인다. 약리작용은 진해, 이뇨, 혈압강하, 진정, 진통, 해열, 진경, 항균작용 등이 보고되었다.Epidermis is a diuretic that treats seawater and asthma caused by waste heat. It is used for acute pyelonephritis and fragile edema. It has a blood pressure-lowering effect and is also used for nosebleeds and keratosis. It is also used for epidemic hepatitis. Pharmacological action is reported by Jinhae, diuresis, lowering blood pressure, sedation, analgesic, fever, jingyeong, antibacterial action.
시호는 산형과에 속하는 다년생 초본식물의 주요 약용작물 중의 하나로서 뿌리에는 사이코사포닌, 스테롤 등의 약리성분이 함유되어 있는 것으로 알려져 한국, 중국, 일본 등지에서 생약재로 이용하고 있다. 항염(anti-inflammatory activity), 간 장애억제(anti-hepatotoxic activity), 진통, 진정, 해열작용 등의 약리효과가 있는 것으로 알려져 있다.Shiho is one of the major medicinal crops of perennial herbaceous plants belonging to the mountain family family, and its roots contain pharmacological components such as psychosaponins and sterols, and are used as herbal medicines in Korea, China and Japan. It is known to have pharmacological effects such as anti-inflammatory activity, anti-hepatotoxic activity, analgesic, sedation, and antipyretic effect.
숙지황은 사물탕(四物湯)의 주요 약재이며 각종 만성병 중 몸이 허약하여 나타나는 내열(內熱), 인후건조(咽喉乾燥), 갈증 등의 증상에 쓰인다. 사물탕은 여성의 출산 후나 월경 등으로 인한 과다출혈, 허약, 어지럼증 등에 널리 쓰인다. 예로부터 허담(虛痰)을 치료하는 데 효과가 있어 차로 달여 마셨으며, 기침과 천식에 복령(茯笭), 반하(半夏) 등과 배합하여 사용하였다.Sukjihwang is the main medicine of Samul-tang (四 物 이며) and is used for symptoms such as heat resistance, dry throat, and thirst caused by the weakness of various chronic diseases. Samultang is widely used for women with excessive bleeding, weakness, and dizziness due to postpartum and menstruation. It has been effective in treating hudam since ancient times, and it was drunk as a tea, and it was used in combination with cough and asthma in Bokryeong (반 夏).
본 발명의 생약 조성물은 상기 천화분은 16~20 중량부, 지초는 5~6 중량부, 상백피는 1.5~2.1 중량부, 시호 및 숙지황은 각각 0.7~1.1 중량부로 포함할 수 있다.The herbal composition of the present invention may include 16 to 20 parts by weight of the cheonhwa, 5 to 6 parts by weight of the grass, baekbaekpi 1.5 to 2.1 parts by weight, Shiho and Sukji sulfur in 0.7 to 1.1 parts by weight, respectively.
또한, 본 발명은 이뇨 작용에 사용되는 생약재, 순환기를 돕기 위한 생약재, 소화흡수를 돕기 위하여 사용되는 생약재, 면역기능을 돕기 위하여 사용되는 생약재 및, 보호제 및 안정제로 사용되는 생약재의 추출물과, 이온성 미네랄을 더 포함하여 이루어지는 혈당 강하 생약 조성물을 제공한다.In addition, the present invention is an herbal medicine used for diuretic action, herbal medicine to help the circulatory system, herbal medicine used to help digestion absorption, herbal medicine used to help immune function, and extracts of herbal medicine used as a protective agent and stabilizer, and ionic It provides a blood sugar-lowering herbal composition further comprising a mineral.
상기 이뇨 작용에 사용되는 생약재는 택사, 저령, 복령, 목통, 통초, 토복령 등을 더 포함할 수 있다. 이때, 이뇨 작용에 사용되는 생약재의 첨가량은 각각 3~4 중량부로 하여 첨가될 수 있다. 상기 이뇨 작용에 사용되는 생약재는 체내의 요산을 배출하여 주며, 상부로 뜨는 열감을 내려주고 혈행을 맑게 도와줄 수 있다. The herbal medicine used for the diuretic action may further include taxa, geryeong, bokyeong, keg, Tongcho, bokbokyeong. At this time, the amount of the herbal medicine used for the diuretic action may be added to each of 3 to 4 parts by weight. The herbal medicine used for the diuretic action to discharge the uric acid in the body, to lower the heat floating to the top can help clear the blood circulation.
또한, 상기 순환기를 돕기 위한 생약재는 두충, 소목, 진피, 오가피, 백단향 등을 포함할 수 있다. 이때, 상기 순환기를 돕기 위한 생약재의 첨가량은 진피는 1.5~2.1 중량부로, 두충, 소목, 오가피 및 백단향은 각각 0.7~1.1 중량부로 첨가될 수 있다. 상기 순환기를 돕기 위한 생약재는 혈당 수치의 상승에 의해 점성이 증가된 혈액을 맑게하고, 혈행을 도와 심장순환기를 원활하게 할 수 있다. In addition, the herbal medicine to help the circulatory may include a larvae, joiner, dermis, scabies, sandalwood and the like. At this time, the added amount of the herbal medicine to help the circulator may be 1.5 ~ 2.1 parts by weight of dermis, tofu, joiner, scabies and sandalwood may be added to 0.7 ~ 1.1 parts by weight, respectively. The herbal medicine to help the circulatory system to clear the blood viscosity is increased by the increase in blood sugar level, help the blood circulation can facilitate the cardiac cycle.
또한, 상기 소화흡수를 돕기 위한 생약재는 맥아, 신곡, 계피, 후박, 목향, 건강 등을 포함할 수 있다. 이때, 상기 소화흡수를 돕기 위하여 사용되는 생약재의 첨가량은 맥아 및 신곡은 각각 5~6 중량부로, 계피, 후박, 목향 및 건강은 각각 1.5~2.1 중량부로 첨가될 수 있다. 상기 소화흡수를 돕기 위한 생약재는 냉성 생약의 소화와 흡수를 촉진하여 냉성 생약의 약효를 증대시킬 수 있다. In addition, the herbal medicine to assist in digestion and absorption may include malt, new song, cinnamon, grommets, throat and health. At this time, the added amount of the herbal medicine used to help the digestive absorption may be added to 5 to 6 parts by weight of malt and new song, respectively, cinnamon, grommets, throat and health of 1.5 to 2.1 parts by weight. The herbal medicine to help the digestive absorption may promote the digestion and absorption of the cold herbal medicine to increase the efficacy of the cold herbal medicine.
또한, 상기 면역기능을 돕기 위하여 사용되는 생약재는 대계, 유근피, 상기생, 하수오, 백자인, 행인 등을 포함할 수 있다. 이때, 상기 면역기능을 돕기 위하여 사용되는 생약재의 첨가량은 대계는 5~6 중량부로, 유근피, 상기생 및 하수오는 각각 1.5~2.1 중량부로, 백자인 및 행인 각각 0.7~1.1 중량부로 하여 첨가될 수 있다. 상기 면역 기능을 돕기 위하여 사용되는 생약재는 세포의 산소이용률을 높여주고, 산화방지제로도 사용이 가능하여 당뇨병의 합병증의 예방을 도와 줄 수 있다.In addition, the herbal medicines used to help the immune function may include daegye, yugeunpi, sanghae, sewage, white porcelain, almonds and the like. At this time, the amount of the herbal medicine used to help the immune function may be added as 5 ~ 6 parts by weight, Yu-Geun Skin, the raw and sewage 1.5 to 2.1 parts by weight, respectively, 0.7 to 1.1 parts by weight of white porcelain and almonds. The herbal medicine used to help the immune function increases the oxygen utilization rate of the cells, can also be used as an antioxidant can help prevent the complications of diabetes.
또한, 상기 보호제 및 안정제로 사용되는 생약재는 당귀, 천궁, 작약, 용안육, 산수유, 현호색, 진범, 대추, 감초 등을 포함할 수 있다. 이때, 상기 보호제 및 안정제로 사용되는 생약재의 첨가량은 현호색, 진범, 용안육, 대추, 산수유 및 감초는 각각 1.5~2.1 중량부로, 당귀, 천궁 및 작약은 각각 0.7~1.1 중량부로 첨가될 수 있다. 상기 보호제 및 안정제로 사용되는 생약재는 당귀, 천궁, 작약, 용안육, 산수유 등은 조혈작용을 나타내는 생약으로 보약개념이 있으며, 현호색, 진범, 대추, 감초 등은 신경 안정 작용이 있어서, 신경계를 이완시켜 주고, 상기 조절 작용 약제와 상호 교량 역할로서 원만하게 신진대사를 촉진할 수 있다.In addition, the herbal medicines used as the protective agent and stabilizer may include Angelica, Cheongung, Peony, Longan meat, Cornus, Hyunho color, Jinbum, Jujube, Licorice and the like. At this time, the amount of the herbal medicine used as the protective agent and stabilizer may be added to Hyunho color, Jinbeom, longan meat, jujube, cornus oil and licorice 1.5 to 2.1 parts by weight, respectively, Angelica, Cheongung and Peony 0.7 to 1.1 parts by weight. The herbal medicine used as the protective agent and stabilizer is Angelica, Cheongung, Peony, Longan meat, cornus milk, etc. The herbal medicine exhibits a hematopoietic effect. And as a bridge to the modulatory agent, it can smoothly promote metabolism.
또한, 상기 이온성 미네랄은 탄산칼륨, 탄산칼슘, 산화마그네슘, 구연산철, 황산아연, 황산망간, 황산구리 등을 첨가할 수 있다. 이때, 상기 이온성 미네랄의 첨가량은 0.15~0.21 중량부로 첨가될 수 있다. 상기 이온성 미네랄은 전기적 기능으로서 생약이 가지고 있는 무기질과 인체내 무기질의 전해질 교량 역할로서 작용하고, 인체의 교감 신경와 함께 약성을 빠르게 나타내도록 하여 약성의 효율을 높일 수 있다.In addition, the ionic mineral may be potassium carbonate, calcium carbonate, magnesium oxide, iron citrate, zinc sulfate, manganese sulfate, copper sulfate and the like. In this case, the amount of the ionic mineral added may be added in 0.15 ~ 0.21 parts by weight. The ionic mineral acts as an electrolyte bridge between the minerals in the herbal and the human body as an electrical function, and can increase the efficiency of weakness by quickly showing the weakness with the sympathetic nerve of the human body.
본 발명에 대한 상기 생약 조성물의 가장 바람직한 예로는, 천화분은 16~20 중량부, 대계, 맥아, 지초 및 신곡은 각각 5~6 중량부, 택사, 저령, 통초, 복령, 목통 및 토복령은 각각 3~4 중량부, 상백피, 유근피, 상기생, 지구자, 현호색, 진범, 용안육, 대추, 계피, 후박, 목향, 건강, 산수유, 하수오, 진피 및 감초는 각각 1.5~2.1 중량부, 당귀, 천궁, 작약, 숙지황, 백자인, 소목, 두충, 오가피, 시호, 행인 및 백단향은 각각 0.7~1.1 중량부로 첨가하고, 여기에 효과를 증진하기 위하여 정제된 이온성 미네랄로서, 탄산칼륨 0.06~0.085 중량부, 탄산칼슘 0.04~0.05 중량부, 산화마그네슘 0.04~0.05 중량부, 구연산철 0.007~0.010 중량부, 황산아연 0.004~0.005 중량부, 황산망간 0.002~0.004 중량부 및 황산구리 0.0005~0.0007 중량부를 더 첨가할 수 있다.In the most preferred example of the herbal composition for the present invention, the natural ingredients are 16 to 20 parts by weight, the base, malt, grass and new songs are 5 to 6 parts by weight, respectively, Taeksa, ghost, Tongcho, Bokryeong, keg and bokbokyeong each 3 ~ 4 parts by weight, lettuce, euneunpi, sanggi, earth, hyunho color, jinbeom, longan meat, jujube, cinnamon, thick, neck, health, cornus, sewage, dermis and licorice, respectively, 1.5 ~ 2.1 parts by weight, donkey, cheongung, Peony, Sukjihwang, White porcelain, Joiner, Tobacco, Ogapi, Siho, Hangin and Sandalwood are added at 0.7-1.1 parts by weight, respectively, and are purified ionic minerals to enhance the effect. 0.04 to 0.05 parts by weight of calcium, 0.04 to 0.05 parts by weight of magnesium oxide, 0.007 to 0.010 parts by weight of iron citrate, 0.004 to 0.005 parts by weight of zinc sulfate, 0.002 to 0.004 parts by weight of manganese sulfate, and 0.0005 to 0.0007 parts by weight of copper sulfate. .
또한, 본 발명은 천화분, 지초, 상백피, 시호 및 숙지황에 이뇨 작용에 사용되는 생약재, 순환기에 사용되는 생약재, 소화흡수를 돕기 위하여 사용되는 생약재, 면역기능을 돕기 위하여 사용되는 생약재 및, 보호제 및 안정제로 사용되는 생약재로 이루어지는 군으로부터 선택되는 1종 이상을 혼합하고, 가열하여 추출물을 얻고, 이온성 미네랄을 첨가하여 이루어지는 혈당 강하 생약 조성물의 제조방법을 제공한다.In addition, the present invention is a herbal medicine used for diuretic action in cheonhwabun, vinegar, baekbaekpi, shiho and sukjihwang, herbal medicine used for circulatory, herbal medicine used for digestive absorption, herbal medicine used to help immune function, and protection and stabilizer Provided is a method for producing a blood sugar lowering herbal composition comprising a mixture of at least one selected from the group consisting of herbal medicines used as a mixture, heating to obtain an extract, and adding ionic minerals.
상기 천화분, 지초, 상백피, 시호, 숙지황 등은 생약재 중에서 냉성을 갖는 약재로서, 특별히 한정하지는 않으나, 구입하거나, 제배된 것을 사용할 수 있으며, 사용되는 형태는 특별히 한정되지는 않는다. 이때, 상기 냉성을 갖는 약재인 천화분은 16~20 중량부, 지초는 5~6 중량부, 상백피는 1.5~2.1 중량부, 시호 및 숙지황은 각각 0.7~1.1 중량부로 첨가될 수 있다.The cheonhwa flour, vinegar, baekbaekpi, shiho, sujijihwang and the like as cold medicine in herbal medicines, although not particularly limited, can be purchased or cultivated, and the form used is not particularly limited. At this time, the medicinal herbs having coldness is 16 to 20 parts by weight, 5 to 6 parts by weight of grass, baekbaekpi is 1.5 to 2.1 parts by weight, shiho and sujijihwang may be added to 0.7 to 1.1 parts by weight, respectively.
또한, 상기 이뇨 작용에 사용되는 생약재는 택사, 저령, 복령, 목통, 통초, 토복령 등을 사용할 수 있으며, 이때 상기 이뇨 작용에 사용되는 생약재의 첨가량은 각각 3~4 중량부로 첨가될 수 있다.In addition, the herbal medicine used for the diuretic action may be used, such as taxa, seolyeong, bokyeong, keg, Tongcho, bokbokyeong, etc. In this case, the amount of the herbal medicine used for the diuretic action may be added in 3 to 4 parts by weight, respectively.
또한, 상기 순환기에 사용되는 생약재는 두충, 소목, 진피, 오가피, 백단향 등을 사용할 수 있으며, 이때 상기 순환기에 사용되는 생약재의 첨가량은 진피는 1.5~2.1 중량부로, 두충, 소목, 오가피 및 백단향은 각각 0.7~1.1 중량부로 하여 첨가될 수 있다.In addition, the herbal medicines used in the circulator may be headed, soybean, dermis, organo, sandalwood, etc., wherein the amount of the herbal medicines used in the circulator is 1.5 to 2.1 parts by weight of dermis, soybeans, joiner, organza and sandalwood. 0.7 to 1.1 parts by weight may be added.
또한, 상기 소화흡수를 돕기 위하여 사용되는 생약재는 맥아, 신곡, 계피, 후박, 목향, 건강 등을 사용할 수 있으며, 이때 상기 소화흡수를 돕기 위하여 사용되는 생약재의 첨가량은 맥아 및 신곡은 각각 5~6 중량부로, 계피, 후박, 목향 및 건강은 각각 1.5~2.1 중량부로 하여 첨가될 수 있다.In addition, the herbal medicine used to help the digestive absorption may be used malt, new song, cinnamon, thick, neck, health, etc. At this time, the amount of the herbal medicine used to help the digestive absorption is malt and new song respectively 5-6 By weight, cinnamon, groceries, throat and health may be added at 1.5 to 2.1 parts by weight, respectively.
또한, 상기 면역기능을 돕기 위하여 사용되는 생약재는 대계, 유근피, 상기생, 하수오, 백자인, 행인 등을 사용할 수 있으며, 이때 상기 면역기능을 돕기 위하여 사용되는 생약재의 첨가량은 대계는 5~6 중량부로, 유근피, 상기생 및 하수오는 각각 1.5~2.1 중량부로, 백자인 및 행인은 각각 0.7~1.1 중량부로 하여 첨가될 수 있다.In addition, the herbal medicines used to help the immune function may be used, such as Daegye, Yugeunpi, the raw, sewage, white porcelain, algae, etc. At this time, the amount of the herbal medicines used to aid the immune function is 5-6 parts by weight, Yu-Geun-pi, said fresh and sewage may be added at 1.5 to 2.1 parts by weight, respectively, and white to 0.7% by weight.
또한, 상기 보호제 및 안정제로 사용되는 생약재는 당귀, 천궁, 작약, 용안육, 산수유, 현호색, 진범, 대추, 감초 등을 사용할 수 있으며, 이때 상기 보호제 및 안정제로 사용되는 생약재의 첨가량은 현호색, 진범, 용안육, 대추, 산수유 및 감초는 각각 1.5~2.1 중량부로, 당귀, 천궁 및 작약은 각각 0.7~1.1 중량부로 하여 첨가될 수 있다.In addition, the herbal medicine used as the protective agent and stabilizer may be used Angelica, Cheongung, Peony, longan meat, cornus, Hyunho color, Jinbeom, jujube, licorice, etc., wherein the amount of the herbal medicine used as the protective agent and stabilizer is Hyunho color, Jinbeom, Longan meat, jujube, cornus and licorice may be added at 1.5 to 2.1 parts by weight, respectively, and Angelica, Cheongung and Peony at 0.7 to 1.1 parts by weight, respectively.
상기 천화분, 지초, 상백피, 시호 및 숙지황에, 이뇨 작용에 사용되는 생약재, 순환기에 사용되는 생약재, 소화흡수를 돕기 위하여 사용되는 생약재, 면역기능을 돕기 위하여 사용되는 생약재 및, 보호제 및 안정제로 사용되는 생약재의 추출은 당업계의 통상적인 방법으로 하여 추출할 수 있으며, 바람직하게는 상기 생약 재를 혼합하고, 상기 혼합된 생약재 총중량에 대해서 3~4배의 물을 가한 후, 열을 가하여 추출물을 얻을 수 있다. The medicinal herb used for diarrhea, herbal medicine used for diuretic action, herbal medicine used for circulatory cycle, herbal medicine used for digestive absorption, herbal medicine used for helping immune function, and protective agent and stabilizer Extraction of the herbal medicine can be extracted by a conventional method in the art, preferably mixing the herbal medicine, adding 3 to 4 times water to the total weight of the mixed herbal medicine, and then applying heat to obtain the extract Can be.
또한, 상기 추출물에 인체 친화와 상기 추출물의 혈당 강하 효율을 증진시키기 위하여 이온성 미네랄을 더 첨가하여 생약 조성물을 제조할 수 있다. 상기 이온성 미네랄은 당업계에서 사용되는 것이라면, 특별히 한정되지는 않으며, 바람직하게는 탄산칼륨, 탄산칼슘, 산화마그네슘, 구연산철, 황산아연, 황산망간, 황산구리 등을 사용할 수 있다. 이때, 상기 이온성 미네랄의 첨가량은 0.15~0.21 중량부로 하여 첨가될 수 있다.In addition, the herbal composition may be further added to the extract in order to enhance human friendliness and blood sugar lowering efficiency of the extract, thereby preparing a herbal composition. The ionic mineral is not particularly limited as long as it is used in the art, and preferably potassium carbonate, calcium carbonate, magnesium oxide, iron citrate, zinc sulfate, manganese sulfate, copper sulfate, or the like can be used. At this time, the amount of the ionic minerals added may be added as 0.15 ~ 0.21 parts by weight.
또한, 본 발명은 천화분, 지초, 상백피, 시호 및 숙지황의 혼합 추출물을 유효성분으로 하고, 약제학적으로 허용되는 방법으로 제형화된 혈당 강하용 약학 제제를 제공한다.In addition, the present invention provides a pharmaceutical preparation for lowering blood sugar, which is formulated in a pharmaceutically acceptable method, using a mixed extract of cheonhwa flour, vinegar, baekbaekpi, shiho and sukji sulfur as an active ingredient.
본 발명에 따른 생약 조성물을 3T3-L1 지방세포에 처리하였을 경우, 상기 천화분, 지초, 상백피, 시호, 숙지황 각각을 포함하는 생약 조성물의 포도당 흡수량은 최소 15±0.43에서 최대 33±2.1로 나타난 반면에, 천화분, 지초, 상백피, 시호 및 숙지황을 포함하는 생약 조성물은 최소 103±1.6에서 최대 142±3.4로 나타나, 본 발명에 따른 생약 조성물은 혈당 강하 조성물로서 유용하게 사용될 수 있으며, 상기 천화분, 지초, 상백피, 시호 및 숙지황을 유효성분으로 하는 생약 조성물을 인슐린 의존성, 인슐린 비의존성 및 당뇨병 경증 환자들이 복용할 경우, 기존의 혈당 강하제보다, 단기간에 혈당 수치를 낮출 수 있어, 당뇨병 환자에게 유용하게 사 용될 수 있다.When the herbal composition according to the present invention was treated to 3T3-L1 adipocytes, the glucose uptake of the herbal composition comprising each of cheonhwa flour, lichen, baekbaekpi, shiho and sukji sulfur was shown to be at least 15 ± 0.43 and at most 33 ± 2.1 Herbal medicine composition comprising, cheonhwa flour, vinegar, baekryepi, shiho and sukji sulfur appear from a minimum of 103 ± 1.6 to a maximum of 142 ± 3.4, the herbal composition according to the present invention can be usefully used as a blood sugar lowering composition, In the case of taking insulin-dependent, insulin-independent, and diabetic patients with herbal compositions containing baekbaekpi, shiho, and succinate sulfur as active ingredients, blood glucose levels can be lowered in a shorter period of time than conventional hypoglycemic agents, and thus may be useful for diabetics. Can be.
상기 생약 조성물의 복용방법은 액상으로 하여 복용하거나, 상기 생약추출물에 이온성 미네랄을 첨가한 추출액을 건조, 분쇄하여 분말 형태로 복용하거나, 상기 분말형태에 백밀 또는 조청을 혼합하여 환약으로 제조하여 복용할 수도 있다.The method of taking the herbal composition is taken in liquid form, or dried and pulverized extracts added with ionic minerals to the herbal extracts to be taken in powder form, or mixed with white wheat or syrup to the powder form to prepare as a pill You may.
본 발명에 따른 생약 조성물은, 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 제조할 수 있다. 약제학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로스 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당 분야의 적정한 방법으로 또는 Remington's Pharmaceutical Science(Mack Publishing Company, Easton PA, 18th, 1990)에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.The herbal composition according to the present invention may be prepared by including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients for administration. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, as necessary, including antioxidants, buffers, Other conventional additives such as bacteriostatic agents can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
본 발명의 생약 조성물은 목적하는 방법에 따라 비경구 투여(예를 들어 정맥 내, 피하, 복강 내 또는 국소에 적용)하거나 경구 투여할 수 있으며, 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하다. 본 발명에 따른 생약 추출물의 일일 투여량은 10 ~ 2,000 ㎎/㎏이며, 바람직하게는 50 ~ 500 ㎎/㎏이다.The herbal composition of the present invention may be administered parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) or orally, depending on the desired method, and the dosage is based on the weight, age, sex and health of the patient. The range varies depending on the diet, the time of administration, the method of administration, the rate of excretion and the severity of the disease. The daily dosage of the herbal extract according to the present invention is 10 to 2,000 mg / kg, preferably 50 to 500 mg / kg.
본 발명의 생약 조성물을 마우스에 경구 투여하여 독성 실험을 수행한 결과, 경구 투여 독성시험에 의한 50% 치사량(LD50)은 적어도 1 g/㎏ 이상인 안전한 물질로 판단된다.As a result of oral administration of the herbal composition of the present invention to mice, 50% lethal dose (LD 50 ) by oral administration toxicity test was determined to be a safe substance of at least 1 g / kg or more.
본 발명의 생약 조성물은 당뇨병의 예방 및 치료를 위하여 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The herbal composition of the present invention may be used alone or in combination with methods using surgery, hormonal therapy, drug therapy and biological response modifiers for the prevention and treatment of diabetes.
본 발명의 생약 조성물은 당뇨 질환의 개선을 목적으로 건강식품에 첨가될 수 있다. 본 발명의 생약 조성물을 식품 첨가물로 사용할 경우, 상기 생약 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에는 본 발명의 생약 추출물은 원료에 대하여 0.01 ~ 10 중량부, 바람직하게는 0.05 ~ 1 중량부의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The herbal composition of the present invention may be added to a health food for the purpose of improving diabetes disease. When the herbal composition of the present invention is used as a food additive, the herbal composition may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment). In general, in the manufacture of food or beverage, the herbal extract of the present invention is added in an amount of 0.01 to 10 parts by weight, preferably 0.05 to 1 part by weight based on the raw materials. However, in the case of long-term intake for health and hygiene or health control purposes, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크 제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, and drinks. Alcoholic beverages and vitamin complexes, and includes all of the health foods in the conventional sense.
본 발명의 건강음료 생약 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 생약 조성물 100 ㎖당 일반적으로 약 0.01 ~ 0.04 g, 바람직하게는 약 0.02 ~ 0.03 g 이다.The healthy beverage herbal composition of the present invention may contain various flavors or natural carbohydrates and the like as an additional component like a normal beverage. The above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the herbal composition of the present invention.
상기 외에 본 발명의 생약 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the herbal composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonation agents used in carbonated beverages. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명을 더욱 상세하게 설명하기 위한 실시예 및 실험예를 제시한 다. 그러나 하기의 실시예 및 실험예는 본 발명을 보다 쉽게 설명하기 위하여 제공되는 것일 뿐, 이에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, examples and experimental examples for explaining the present invention in more detail. However, the following Examples and Experimental Examples are only provided to explain the present invention more easily, and the contents of the present invention are not limited thereto.
<< 실시예Example 1> 생약 조성물의 제조 1 1> Preparation of herbal composition 1
천화분은 16~20 중량부, 지초는 5~6 중량부, 상백피는 1.5~2.1 중량부, 시호 및 숙지황은 0.7~1.1 중량부로 혼합하고, 여기에 생약재 총중량에 대하여 물을 3~4배를 가한 후, 100 ℃에서 2~3시간 동안 가열하여 추출물을 얻고, 이를 멸균하여 생약 조성물을 제조하였다.16 to 20 parts by weight of cheonhwa, 5 to 6 parts by weight of ground grass, 1.5 to 2.1 parts by weight of baekbaekpi, and 0.7 to 1.1 parts by weight of Siho and Sukji sulfur, and added 3 to 4 times of water to the total weight of herbal medicines. Thereafter, the mixture was heated at 100 ° C. for 2 to 3 hours to obtain an extract, and sterilized to prepare a herbal composition.
<< 실시예Example 2> 생약 조성물의 제조 2 2> Preparation of herbal composition 2
천화분은 16~20 중량부, 지초는 5~6 중량부, 상백피는 1.5~2.1 중량부, 시호 및 숙지황은 0.7~1.1 중량부, 택사, 저령, 통초, 복령, 목통, 토복령 각각을 3~4 중량부로 혼합하고, 여기에 생약재 총중량에 대하여 물을 3~4배를 가한 후, 100 ℃에서 2~3시간 동안 가열하여 추출액을 얻고, 이를 멸균하여 생약 조성물을 제조하였다.16 ~ 20 parts by weight of Cheonhwa, 5 ~ 6 parts by weight of ground grass, 1.5 ~ 2.1 parts by weight of Sangbaekpi, 0.7 ~ 1.1 parts by weight of Siho and Sukjiwang, 3 ~ 3 each of Taxi, Angel, Tongcho, Bokryeong, Keg, and Bokbokyeong After mixing to 4 parts by weight, water was added 3 to 4 times the total weight of the herbal medicine, and then heated at 100 ℃ for 2 to 3 hours to obtain an extract, sterilized it to prepare a herbal composition.
<< 실시예Example 3> 생약 조성물의 제조 3 3> Preparation of herbal composition 3
천화분은 16~20 중량부, 지초는 5~6 중량부, 상백피 및 진피는 1.5~2.1 중량부, 시호, 숙지황, 두충, 소목, 오가피 및 백단향은 0.7~1.1 중량부로 혼합하고, 여기에 생약재 총중량에 대하여 물을 3~4배를 가한 후, 100 ℃에서 2~3시간 동안 가열하여 추출물을 얻고, 이를 멸균하여 생약 조성물을 제조하였다.16-20 parts by weight of cheonhwa, 5-6 parts by weight of the ground, 1.5 ~ 2.1 parts by weight of baekhwapi and dermis, mixed with 0.7 ~ 1.1 parts by weight of Shiho, Sukjihwang, tofu, Joiner, Ogapi and sandalwood. Water was added 3 to 4 times, and the extract was obtained by heating at 100 ° C. for 2 to 3 hours, and sterilizing the same to prepare a herbal composition.
<< 실시예Example 4> 생약 조성물의 제조 4 4> Preparation of herbal composition 4
천화분은 16~20 중량부, 지초, 맥아 및 신곡는 5~6 중량부, 상백피, 계피, 후박, 목향 및 건강은 1.5~2.1 중량부, 시호 및 숙지황은 0.7~1.1 중량부로 혼합하고, 여기에 생약재 총중량에 대하여 물을 3~4배를 가한 후, 100 ℃에서 2~3시간 동안 가열하여 추출물을 얻고, 이를 멸균하여 생약 조성물을 제조하였다.16-20 parts by weight of cheonhwa, 5-6 parts by weight of vinegar, malt and new song, 1.5-2.1 parts by weight of baekhyeol, cinnamon, thick pepper, throat and health, and 0.7-1.1 parts by weight of shiho and sujijihwang. Water was added 3 to 4 times the total weight, and then heated at 100 ° C. for 2 to 3 hours to obtain an extract, which was sterilized to prepare a herbal composition.
<< 실시예Example 5> 생약 조성물의 제조 5 5> Preparation of herbal composition 5
천화분은 16~20 중량부, 지초 및 대계는 5~6 중량부, 상백피, 유근피, 상기생 및 하수오는 1.5~2.1 중량부, 시호, 숙지황, 백자인 및 행인은 0.7~1.1 중량부로 혼합하고, 여기에 생약재 총중량에 대하여 물을 3~4배를 가한 후, 100 ℃에서 2~3시간 동안 가열하여 추출물을 얻고, 이를 멸균하여 생약 조성물을 제조하였다.16 ~ 20 parts by weight of cheonhwa, 5 ~ 6 parts by weight of ground grass and base, mixed with white and white skin, Yugeunpi, 1.5 ~ 2.1 parts by weight of sesame seeds and sewage, and 0.7 ~ 1.1 parts by weight of Siho, Sukji sulfur, white porcelain and almonds. Water was added 3 to 4 times the total weight of the herbal medicines, and then heated at 100 ° C. for 2 to 3 hours to obtain an extract, which was sterilized to prepare a herbal composition.
<< 실시예Example 6> 생약 조성물의 제조 6 6> Preparation of herbal composition 6
천화분은 16~20 중량부, 지초는 5~6 중량부, 상백피, 현호색, 진범, 용안육, 대추, 산수유 및 감초는 1.5~2.1 중량부, 시호, 숙지황, 당귀, 천궁 및 작약은 0.7~1.1 중량부로 혼합하고, 여기에 생약재 총중량에 대하여 물을 3~4배를 가한 후, 100 ℃에서 2~3시간 동안 가열하여 추출물을 얻고, 이를 멸균하여 생약 조성물을 제조하였다.16 ~ 20 parts by weight of cheonhwa, 5 ~ 6 parts by weight of green grass, baekbaekpi, Hyunho color, 1.5 ~ 2.1 parts by weight of jinbeom, longan meat, jujube, cornus and licorice, 0.7 ~ 1.1 parts by weight of shiho, sukjiji, donkey, cheongung and peony The mixture was added to the mixture, and water was added to 3 to 4 times the total weight of the medicinal herb, followed by heating at 100 ° C. for 2 to 3 hours to obtain an extract, which was sterilized to prepare a herbal composition.
<< 실시예Example 7> 생약 조성물의 제조 7 7> Preparation of herbal composition 7
천화분 16~20 중량부, 대계, 맥아, 지초, 신곡 각각을 5~6 중량부, 택사, 저령, 통초, 복령, 목통, 토복령 각각을 3~4 중량부, 상백피, 유근피, 상기생, 지구자, 현호색, 진범, 용안육, 대추, 계피, 후박, 목향, 건강, 산수유, 하수오, 진피, 감초 각각을 1.5~2.1 중량부 , 당귀, 천궁, 작약, 숙지황, 백자인, 소목, 두충, 오가피, 시호, 행인, 백단향 각각을 0.7~1.1 중량부를 혼합하고, 여기에 생약재 총중량에 대하여 물을 3~4배를 가한 후, 100 ℃에서 2~3시간 동안 가열하여 추출물을 얻고, 이를 멸균하여 생약 조성물을 제조하였다.16 ~ 20 parts by weight of hwahwa, 5 ~ 6 parts by weight of maltose, malt, grass, and new song, 3 ~ 4 parts by weight of each of talc, ghost, tongcho, bokyeong, keg, bokbokyeong, baekbaekpi, yugeunpi, sanggi, earth , Calendula, jinbum, longan meat, jujube, cinnamon, thick, neck, health, cornus, sewage, dermis, licorice 1.5 ~ 2.1 parts by weight, donkey, cheonggung, peony, sage, white porcelain, joiner, larva, ogapi, shiho, Alginate, sandalwood each 0.7-1.1 parts by weight, mixed with water 3 to 4 times the total weight of the herbal medicine, and then heated at 100 ℃ for 2-3 hours to obtain an extract, sterilized it to prepare a herbal composition It was.
<< 실시예Example 8> 생약 조성물의 제조 8 8> Preparation of herbal composition 8
천화분 16~20 중량부, 대계, 맥아, 지초, 신곡 각각을 5~6 중량부, 택사, 저령, 통초, 복령, 목통, 토복령 각각을 3~4 중량부, 상백피, 유근피, 상기생, 지구자, 현호색, 진범, 용안육, 대추, 계피, 후박, 목향, 건강, 산수유, 하수오, 진피, 감초 각각을 1.5~2.1 중량부 , 당귀, 천궁, 작약, 숙지황, 백자인, 소목, 두충, 오가피, 시호, 행인, 백단향 각각을 0.7~1.1 중량부를 혼합하고, 여기에 생약재 총중량에 대하여 물을 3~4배를 가한 후, 100 ℃에서 2~3시간 동안 가열하여 추출액을 얻었다. 16 ~ 20 parts by weight of hwahwa, 5 ~ 6 parts by weight of maltose, malt, grass, and new song, 3 ~ 4 parts by weight of each of talc, ghost, tongcho, bokyeong, keg, bokbokyeong, baekbaekpi, yugeunpi, sanggi, earth , Calendula, jinbum, longan meat, jujube, cinnamon, thick, neck, health, cornus, sewage, dermis, licorice 1.5 ~ 2.1 parts by weight, donkey, cheonggung, peony, sage, white porcelain, joiner, larva, ogapi, shiho, 0.7-1.1 parts by weight of each of the almonds and almonds were mixed, and water was added thereto 3 to 4 times based on the total weight of the herbal medicine, followed by heating at 100 ° C. for 2 to 3 hours to obtain an extract.
상기 추출액에 대하여 탄산칼륨을 0.06~0.085 중량부, 탄산칼슘 및 산화마그네슘을 0.04~0.05 중량부, 구연산철을 0.007~0.01 중량부, 황산아연을 0.004~0.005 중량부, 황산망간을 0.002~0.004 중량부, 황산구리를 0.0005~0.007 중량부가 되도록 혼합한 이온성 미네랄을 상기 추출물에 0.15~0.21 중량부로 첨가하였고, 이를 멸균하여 생약 조성물을 제조하였다.0.06 to 0.085 parts by weight of potassium carbonate, 0.04 to 0.05 parts by weight of calcium carbonate and magnesium oxide, 0.007 to 0.01 parts by weight of iron citrate, 0.004 to 0.005 parts by weight of zinc sulfate, and 0.002 to 0.004 parts by weight of manganese sulfate Parts, 0.15 to 0.21 parts by weight of ionic minerals mixed to 0.0005 to 0.007 parts by weight of copper sulfate were added to the extract, and sterilized to prepare a herbal composition.
<< 비교예Comparative example 1> 1> 천화분을Flower pot 함유한 생약 조성물의 제조 Preparation of Herbal Compositions Containing
주요 생약재 중에서 천화분만을 16~20 중량부 첨가하고 상기 실시예 8과 동일한 방법으로 하여 생약 조성물을 제조하였다.Only 16-20 parts by weight of cheonhwa was added among the main herbal medicines, and a herbal composition was prepared in the same manner as in Example 8.
<< 비교예Comparative example 2> 2> 지초를Grounding 함유한 생약 조성물의 제조 Preparation of Herbal Compositions Containing
주요 생약재 중에서 지초만을 5~6 중량부 첨가하고 상기 실시예 8과 동일한 방법으로 하여 생약 조성물을 제조하였다.Herbal medicine composition was prepared in the same manner as in Example 8 after adding only 5-6 parts by weight of the main herbal medicine.
<< 비교예Comparative example 3> 상백피를 함유한 생약 조성물의 제조 3> Preparation of Herbal Medicine Composition
주요 생약재 중에서 상백피만을 1.5~2.1 중량부 첨가하고 상기 실시예 8과 동일한 방법으로 하여 생약 조성물을 제조하였다.Only 1.5 to 2.1 parts by weight of the main medicinal herb was added 1.5 to 2.1 parts by weight and the same method as in Example 8 to prepare a herbal composition.
<< 비교예Comparative example 4> 4> 시호을Shiho 함유한 생약 조성물의 제조 Preparation of Herbal Compositions Containing
주요 생약재 중에서 시호만을 0.7~1.1 중량부 첨가하고 상기 실시예 8과 동일한 방법으로 하여 생약 조성물을 제조하였다.Only 0.7-1.1 parts by weight of Shiho was added among the main herbal medicines, and a herbal composition was prepared in the same manner as in Example 8.
<< 비교예Comparative example 5> 숙지황을 함유한 생약 조성물의 제조 5> Preparation of herbal composition containing sulfur
주요 생약재 중에서 숙지황만을 0.7~1.1 중량부 첨가하고 상기 실시예 8과 동일한 방법으로 하여 생약 조성물을 제조하였다.Only 0.7-1.1 parts by weight of Sookji sulfur was added among the main herbal medicines, and a herbal composition was prepared in the same manner as in Example 8.
<< 실험예Experimental Example 1> 지방세포 내로의 포도당 흡수 실험 1> Glucose uptake into adipocytes
생약 조성물의 포도당 흡수 정도를 알아보기 위하여 하기와 같은 실험을 진행하였다.In order to determine the glucose absorption level of the herbal composition was carried out the following experiment.
실험에 사용한 3T3-L1 세포는 미국세포주은행에서 구입하였고, 1% FBS(fetal bovine serum), 젠타마이신(gentamycine, 100 units/㎖), 스트렙토마이신 (streptomycin, 100 ㎍/㎖) 등을 첨가한 DMEM(Dulbecco's modified Eagle's medium) 배지에서 배양하였다.The 3T3-L1 cells used in the experiment were purchased from the American Cell Line Bank, and added DMEM with 1% fetal bovine serum (FBS), gentamycine (100 units / ml) and streptomycin (streptomycin (100 µg / ml)). Cultured in (Dulbecco's modified Eagle's medium) medium.
3T3-L1 섬유아세포를 디스크에 완전히 채워질 (confluent) 때까지 배양하였다. 배양용기 바닥을 완전히 채운 지 2일 후에 유도분화물질인 덱사메타손(dexamethasone) 0.25μM을 넣어 3일 동안 배양한 후 2일에 한 번씩 고농도 포도당 DMEM 용액으로 새로 바꾸어 주어 지방세포로 완전히 전환된 10~15일 사이에 포도당 흡수 실험을 하였다.3T3-L1 fibroblasts were incubated until the disc was completely confluent. Two days after the bottom of the culture vessel was completely filled, 0.25 μM of derivatized dexamethasone was added and cultured for three days, and then changed into high-density glucose DMEM solution once every two days to completely convert into fat cells. Glucose uptake was done between days.
배양용기에 있는 지방세포의 수를 세어 12 웰 플레이트의 웰을 빈 공간없이 완전히 채울 수 있도록 분주하였다. 웰 플레이트에 옮긴 지방세포를 PBS로 세척한 후 1% 소 혈청알부민(bovine serum albumin)을 함유하고 있는 저농도의 포도당을 함유한 DMEM에서 12시간 이상 지난 후에 HEPES 용액에서 37 ℃에서 30분 동안 배양 하였다. 여기에 1 μCi/㎖의 [14C]2-데옥시글루코스와 1 mM 포도당을 첨가하고 22 ℃에서 30분 동안 배양하여 포도당의 세포내로의 흡수 정도를 14C가 세포내로 이동한 양으로 측정하였다.The number of adipocytes in the culture vessel was counted and dispensed so that the wells of the 12 well plates could be completely filled without empty space. Adipose cells transferred to well plates were washed with PBS and incubated for 30 minutes at 37 ° C. in HEPES solution after 12 hours in DMEM containing low glucose containing 1% bovine serum albumin. . 1 μCi / mL of [ 14 C] 2-deoxyglucose and 1 mM glucose were added thereto, followed by incubation at 22 ° C. for 30 minutes, and the degree of glucose uptake into cells was measured by the amount of 14 C transferred into cells. .
비특이적인 포도당 흡수를 배제하기 위해서 글루코스 트랜스포터 4(glucose transporter 4; GLUT4)의 작용을 억제하는 사이토 B(cyto B)와 함께 배양하였을 때의 포도당 이동량을 빼고 세포내로 이동한 포도당의 양을 측정하였다.In order to rule out nonspecific glucose uptake, the amount of glucose transported into the cell was measured by subtracting the glucose shift when incubated with cyto B, which inhibits the action of glucose transporter 4 (GLUT4). .
상기 실시예 1~8 및 비교예 1~5에서 제조된 생약 추출물을 DMSO에 1 ㎎/㎖로 녹이고 PBS로 3 ㎍/㎖로 희석하여 3T3-L1 지방세포에 처리하였다. 이를 1시간 동안 배양하였다. 배양된 세포는 10 mM 포도당이 함유된 PBS로 세척하고 0.5 N 수산화나트륨으로 세포를 분해시켰다. 분해된 세포를 초산으로 중화시키고 함유된 14C의 함량을 베타 카운터(Tri-Carb 2100TR, Packard Bioscince, IL)로 측정하였고, 그 결과를 하기 표 1에 나타내었다.The herbal extracts prepared in Examples 1 to 8 and Comparative Examples 1 to 5 were dissolved at 1 mg / ml in DMSO, diluted to 3 μg / ml with PBS, and treated with 3T3-L1 adipocytes. It was incubated for 1 hour. Cultured cells were washed with PBS containing 10 mM glucose and digested with 0.5 N sodium hydroxide. The lysed cells were neutralized with acetic acid and the content of 14 C was measured by a beta counter (Tri-Carb 2100TR, Packard Bioscince, IL), and the results are shown in Table 1 below.
(* 상기 데이타는 평균±표준편차로 나타냄)(* The above data is expressed as mean ± standard deviation)
상기 표 1에 나타난 바와 같이, 용매인 DMSO만 처리하였을 경우에 세포내로 당 흡수율이 거의 증가하지 않았으나, 비교예 1~5의 생약 조성물을 투여하였을 경우, 세포내로 포도당의 흡수가 미미하게 나타남을 알 수 있었다. 이와는 달리, 상기 실시예 1~8의 생약 조성물을 처리한 세포군은 세포내 포도당 흡수가 크게 증가함을 알 수 있었다. 특히, 실시예 8의 이온성 미네랄을 포함하는 생약 조성물에서 가장 높은 당 흡수율이 관찰되었다.As shown in Table 1 above, when only the solvent DMSO was treated, the glucose uptake rate was hardly increased intracellularly. However, when the herbal composition of Comparative Examples 1 to 5 was administered, glucose uptake into the cells was minimal. Could. In contrast, the cell group treated with the herbal compositions of Examples 1 to 8 was found to significantly increase the intracellular glucose uptake. In particular, the highest sugar absorption was observed in the herbal composition comprising the ionic mineral of Example 8.
<< 실험예Experimental Example 2> 인슐린 의존성 2> insulin dependence 환자에서의In the patient 생약 조성물의 효과 Effect of herbal composition
식후 2시간 후에 혈당 수치 250~300인 인슐린 의존성 당뇨병 환자 20명에게 상기 실시예 1~8의 생약 조성물 120~130 ㎖을 1일 3회 복용시켰으며, 대조군으로는 인슐린을 투여하지 않고, 1일 2회 병원에서 제공하는 혈당 강하제 경구용을 복용한 그룹(대조군 1)과 인슐린 조절제와 혈당 강하제를 투여하지 않은 그룹(대조군 2)을 각각 측정하고, 그 결과를 하기 표 2에 나타내었다.Two hours after meals, 20 insulin-dependent diabetic patients with a blood glucose level of 250 to 300 were given three times a day 120 to 130 ml of the herbal composition of Examples 1 to 8, and the control group was not administered insulin, and one day Groups taking oral hypoglycemic drugs provided by two hospitals (control group 1) and groups without insulin control agent and hypoglycemic agent (control group 2) were measured, respectively, and the results are shown in Table 2 below.
상기 표 2에 나타난 바와 같이, 식후 2시간 후에 혈당 수치가 250~300인 인슐린 의존성 당뇨병 환자들에게 혈당 강하제를 투여한 대조군 1의 경우, 6개월 투여 후에는 90%가 혈당치가 160 이하가 되었다. 상기 실시예 1~8의 생약조성물은 모두 혈당 강하 효과를 보였다. 특히, 실시예 8에 의해 제조된 생약 조성물을 복용한 당뇨병 환자의 경우, 4개월 후에는 90% 이상이 혈당치가 250 이하로 떨어졌으며, 특히, 복용 후 5개월 후에는 90% 이상이 혈당치가 160 이하로 떨어져, 기존의 혈당 강하제보다 인슐린 의존성 당뇨병 환자에게 단기간에 더 높은 효과를 보임을 알 수 있었다. As shown in Table 2, in the case of the control group 1, in which insulin-lowering drugs were administered to insulin-dependent diabetic patients having a blood glucose level of 250 to 300 after 2 hours after eating, 90% of the blood glucose levels were 160 or less after 6 months. The herbal compositions of Examples 1 to 8 all showed a hypoglycemic effect. In particular, in the diabetic patients taking the herbal composition prepared according to Example 8, more than 90% of the blood sugar dropped to 250 or less after 4 months, in particular, more than 90% after the 5 months after taking 160 In the following, it can be seen that a higher effect in the short-term in insulin-dependent diabetes patients than conventional hypoglycemic agents.
<< 실험예Experimental Example 3> 인슐린 3> insulin 비의존성Independence 환자에서의In the patient 생약 조성물의 효과 Effect of herbal composition
식후 2시간 후에 혈당 수치 250~300인 인슐린 비의존성 당뇨병 환자 20명에게 상기 실시예 1~8의 생약 조성물 120~130 ㎖을 1일 3회 복용시켰으며, 대조군으로는 1일 2회 병원에서 제공하는 혈당 강하제 경구용을 복용한 그룹(대조군 1)과 혈당 강하제를 투여하지 않은 그룹(대조군 2)을 각각 측정하고, 그 결과를 하기 표 3에 나타내었다. Two hours after a meal, 120 patients with insulin-independent diabetes mellitus having a blood glucose level of 250 to 300 were given 120 to 130 ml of the herbal composition of Examples 1 to 8 three times a day. The group taking the oral glucose lowering agent (control group 1) and the group not receiving the blood glucose lowering agent (control group 2) were measured, respectively, and the results are shown in Table 3 below.
상기 표 3에 나타난 바와 같이, 식후 2시간 후에 혈당 수치가 250~300인 인슐린 비의존성 당뇨병 환자들에게 혈당 강하제를 투여한 대조군 1의 경우, 6개월 투여 후에는 85%가 혈당치가 160 이하가 되었다. 상기 실시예 1~8에 의해 제조된 생약 조성물들은 기존 혈당 강하제보다 높은 효과를 보였으며, 특히, 실시예 8에 의해 제조된 생약 조성물을 복용한 당뇨병 환자의 경우, 5개월 후에는 90% 이상이 혈당치가 250 이하로 떨어졌으며, 특히, 복용 6개월 후에는 90% 이상이 혈당치가 160 이하로 떨어져, 기존의 혈당 강하제보다 인슐린 비의존성 당뇨병 환자에게 단기간에 더 높은 효과를 보임을 알 수 있었다.As shown in Table 3, in the control group 1, in which insulin-independent diabetic patients with blood glucose levels of 250 to 300 after 2 hours after meals, 85% of the blood sugar levels were 160 or less after 6 months. . The herbal compositions prepared by Examples 1 to 8 showed a higher effect than the existing hypoglycemic agents, in particular, in the diabetic patients taking the herbal composition prepared by Example 8, more than 90% after 5 months The blood sugar level dropped to 250 or less. In particular, after 6 months, 90% or more of the blood sugar levels dropped to 160 or less, which showed a higher effect in the short term in patients with insulin-independent diabetes than the conventional hypoglycemic agents.
<< 실험예Experimental Example 4> 인슐린과 경구용 혈당 4> Insulin and Oral Blood Sugar 강하제Hypotensive 비의존형Independent 경증환자에서의In mild patients 생약 조성물의 효과 Effect of herbal composition
식후 2시간 후에 혈당 수치 250~300인 인슐린과 경구용 혈당 강하제 비의존성 당뇨병 경증 환자 20명에게 상기 실시예 8의 생약 조성물 120~130 ㎖을 1일 3회 복용시키고, 각각 측정하였다. 그 결과를 하기 표 4에 나타내었다.Two hours after the meal, 120 to 130 ml of the herbal composition of Example 8 was administered three times a day to 20 patients with diabetes with oral hypoglycemic agents, which had a blood glucose level of 250 to 300, three times a day. The results are shown in Table 4 below.
상기 표 4에 나타난 바와 같이, 식후 2시간 후에 혈당 수치가 250~300인 인슐린과 경구용 혈당 강하제 비의존성 당뇨병 경증 환자들이 실시예 8에 의해 제조된 생약 조성물을 복용시 상기 당뇨병 환자는 5개월 후, 90% 이상이 혈당치가 250 이하로 떨어졌으며, 특히, 복용 6개월 후에는 83% 이상이 혈당치가 160 이하로 떨어져, 실시예 8에 의해 제조된 생약조성물은 기존의 혈당 강하제보다 인슐린과 경구용 혈당 강하제 비의존성 당뇨병 경증 환자에게서 단기간에 더 높은 효과를 보임을 알 수 있었다. As shown in Table 4, the diabetic patients 5 months after taking the herbal composition prepared by Example 8 with insulin having a blood glucose level of 250 to 300 and oral hypoglycemic agent-independent diabetic patients 2 hours after eating , More than 90% of the blood sugar dropped to 250 or less, in particular, more than 83% after six months of taking blood sugar below 160, the herbal composition prepared in Example 8 is more or less insulin and oral than conventional hypoglycemic agents In patients with diabetes mellitus-independent diabetic patients, the effect was higher in a short time.
<< 실험예Experimental Example 5> 미네랄 첨가에 따른 생약 조성물의 혈당 강하 효과 비교 5> Comparison of hypoglycemic effect of herbal composition with mineral addition
식후 2시간 후에 혈당 수치 250~300인 인슐린 비의존성 당뇨병 환자 각각 20명에게 각각 실시예 8 및 실시예 7의 생약 조성물 120~130 ㎖을 1일 3회 복용시키고, 이의 혈당 수치를 측정하였다. 그 결과를 하기 표 5에 나타내었다.Two hours after the meal, each of 20 insulin-independent diabetic patients with blood glucose levels of 250 to 300 was taken 120 to 130 ml of the herbal compositions of Examples 8 and 7 three times a day, and their blood glucose levels were measured. The results are shown in Table 5 below.
상기 표 5에 나타난 바와 같이, 생약 조성물에 이온성 미네랄(전해질)을 첨가한 실시예 8은 생약 조성물에 이온성 미네랄을 첨가하지 않은 실시예 7보다 투약 기간이 길어짐에 따라서 최소 5%에서 최대 12%까지 혈당치가 떨어진 환자가 증가함을 알 수 있었다. 이로 보아, 상기 생약 조성물에서 이온성 미네랄의 첨가는 생약 조성물의 약효를 증대시켜 줄 수 있음을 간접적으로 알 수 있었다.As shown in Table 5, Example 8 in which the ionic mineral (electrolyte) was added to the herbal composition was longer than the example of Example 7 in which the ionic mineral was not added to the herbal composition. It was found that the number of patients whose blood glucose levels fell by% increased. From this, it was found indirectly that the addition of ionic minerals in the herbal composition can increase the efficacy of the herbal composition.
하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of preparations for the compositions of the present invention are illustrated below.
<< 제제예Formulation example 1> 약학적 제제의 제조 1> Preparation of Pharmaceutical Formulations
1-1: 1-1: 산제의Powder 제조 Produce
본 발명에 따른 혼합 추출물 2 g2 g of the mixed extract according to the present invention
유당 1 g1 g lactose
상기의 성분을 혼합한 후, 기밀포에 충진하여 산제를 제조하였다.After mixing the above components, the airtight cloth was filled to prepare a powder.
1-2: 정제의 제조1-2: Preparation of Tablets
본 발명에 따른 혼합 추출물 100 ㎎100 mg of the mixed extract according to the present invention
옥수수전분 100 ㎎Corn starch 100 mg
유 당 100 ㎎Lactose 100 mg
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
1-3: 캡슐제의 제조1-3: Preparation of Capsule
본 발명에 따른 혼합 추출물 100 ㎎100 mg of the mixed extract according to the present invention
옥수수전분 100 ㎎Corn starch 100 mg
유 당 100 ㎎Lactose 100 mg
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
1-4: 주사액제의 제조1-4: Preparation of Injection Solution
본 발명에 따른 혼합 추출물 10 ㎍/㎖10 μg / ml mixed extract according to the present invention
묽은 염산 BP pH 3.5로 될 때까지Dilute hydrochloric acid BP until pH 3.5
주사용 염화나트륨 BP 최대 1 ㎖Injectable sodium chloride BP up to 1 ml
적당한 용적의 주사용 염화나트륨 BP 중에 본 발명에 따른 혼합 추출물을 용해시키고, 생성된 용액의 pH를 묽은 염산 BP를 사용하여 pH 3.5로 조절하고, 주사용 염화나트륨 BP를 사용하여 용적을 조절하고 충분히 혼합하였다. 용액을 투명 유리로 된 5 ㎖ 타입 I 앰플 중에 충전시키고, 유리를 용해시킴으로써 공기의 상부 격자하에 봉입시키고, 120 ℃에서 15 분 이상 오토클래이브시켜 살균하여 주사액제를 제조하였다.The mixed extract according to the present invention was dissolved in an appropriate volume of sodium chloride BP for injection, the pH of the resulting solution was adjusted to pH 3.5 with dilute hydrochloric acid BP, and the volume was adjusted with sodium chloride BP for injection and thoroughly mixed. . The solution was filled into a 5 ml Type I ampoule made of clear glass, encapsulated under an upper grid of air by dissolving the glass, and sterilized by autoclaving at 120 ° C. for at least 15 minutes to prepare an injection solution.
<< 제제예Formulation example 2> 식품의 제조 2> Manufacture of food
본 발명에 따른 혼합 추출물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the mixed extract according to the present invention were prepared as follows.
2-1: 밀가루 식품의 제조2-1: Manufacturing Flour Food
본 발명에 따른 혼합 추출물 0.1 ~ 10.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 통상의 방법으로 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.1 ~ 10.0 parts by weight of the mixed extract according to the present invention was added to the flour, and using the mixture to prepare bread, cake, cookies, crackers and noodles in a conventional manner to prepare foods for health promotion.
2-2: 2-2: 스프soup 및 육즙( And juicy ( graviesgravies )의 제조Manufacturing
본 발명에 따른 혼합 추출물 0.1 ~ 1.0 중량부를 스프 및 육즙에 첨가하여 통상의 방법으로 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1 to 1.0 parts by weight of the mixed extract according to the present invention was added to soups and broth to prepare meat products for health promotion, soups of noodles and broth in a conventional manner.
2-3: 그라운드 2-3: Ground 비프(ground beef)의Ground beef 제조 Produce
본 발명에 따른 혼합 추출물 10 중량부를 그라운드 비프에 첨가하여 통상의 방법으로 건강 증진용 그라운드 비프를 제조하였다.10 parts by weight of the mixed extract according to the present invention was added to ground beef to prepare ground beef for health promotion in a conventional manner.
2-4: 유제품(2-4: Dairy Products ( dairydairy productsproducts )의 제조Manufacturing
본 발명에 따른 혼합 추출물 0.1 ~ 1.0 중량부를 우유에 첨가하고, 상기 우유를 이용하여 통상의 방법으로 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.0.1-1.0 parts by weight of the mixed extract according to the present invention was added to milk, and various dairy products such as butter and ice cream were prepared in a conventional manner using the milk.
2-5: 2-5: 선식의Linear 제조 Produce
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.
본 발명에 따른 혼합 추출물을 진공 농축기에서 감압, 농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The mixed extract according to the present invention was decompressed and concentrated in a vacuum concentrator, and the dried product obtained by drying with a sprayer and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 본 발명에 따른 혼합 추출물 건조분말을 다음의 비율로 배합하여 통상의 방법으로 제조하였다.The grains, seeds and the mixed extract dry powder according to the present invention prepared above were blended in the following ratio to prepare a conventional method.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),
본 발명에 따른 혼합 추출물 건조분말(1 중량부),Mixed extract dry powder (1 part by weight) according to the present invention,
영지(0.5 중량부),Ganoderma lucidum (0.5 parts by weight),
지황(0.5 중량부)Foxglove (0.5 part by weight)
<< 제제예Formulation example 3> 음료의 제조 3> Manufacture of beverage
본 발명에 따른 혼합 추출물을 포함하는 음료를 다음과 같이 제조하였다.A beverage containing the mixed extract according to the present invention was prepared as follows.
3-1: 3-1: 건강음료의Health drink 제조 Produce
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 본 발명에 따른 혼합 추출물을 균질하게 배합하여 순간 살균을 한 후, 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.After instant sterilization by homogeneously mixing the mixed extract according to the present invention with a subsidiary material such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%) To prepare a healthy drink, it was packaged in small packaging containers such as glass bottles and plastic bottles.
3-2: 3-2: 야채쥬스의Vegetable juice 제조 Produce
본 발명에 따른 혼합 추출물 0.5 g을 토마토 또는 당근 등의 야채의 쥬스 1,000 ㎖에 가하여 통상의 방법으로 건강 증진용 야채쥬스를 제조하였다.0.5 g of the mixed extract according to the present invention was added to 1,000 ml of a vegetable juice such as tomato or carrot to prepare a vegetable juice for health promotion in a conventional manner.
3-3: 3-3: 과일쥬스의Fruit juice 제조 Produce
본 발명에 따른 혼합 추출물 0.1 g을 사과 또는 포도 등의 과일의 쥬스 1,000 ㎖에 가하여 통상의 방법으로 건강 증진용 과일쥬스를 제조하였다.0.1 g of the mixed extract according to the present invention was added to 1,000 ml of fruit juice such as apple or grape, thereby preparing a fruit juice for health promotion in a conventional manner.
본 발명에 따른 생약 조성물은 인슐린 의존성 또는 인슐린 비의존성 당뇨병 환자의 혈당 수치를 안정적이고 지속적으로 낮추면서도, 기존의 혈당강하제의 부작용을 최소화하여 경구용 당뇨병 예방 및 치료제로 유용하게 사용될 수 있다.The herbal composition according to the present invention can be usefully used as a preventive and therapeutic agent for oral diabetes by minimizing the side effects of the existing hypoglycemic agents while stably and continuously lowering the blood sugar level of insulin-dependent or insulin-independent diabetes patients.
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060133561A KR100827350B1 (en) | 2006-12-26 | 2006-12-26 | Herbal medicine composition for descending blood sugar |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060133561A KR100827350B1 (en) | 2006-12-26 | 2006-12-26 | Herbal medicine composition for descending blood sugar |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100827350B1 true KR100827350B1 (en) | 2008-05-06 |
Family
ID=39649632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060133561A KR100827350B1 (en) | 2006-12-26 | 2006-12-26 | Herbal medicine composition for descending blood sugar |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100827350B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101216032B1 (en) | 2010-04-29 | 2012-12-31 | 주식회사 미네랄이십일 | Pharmaceutical composition for the treatment and prevention of disease relating diabetes |
KR101540107B1 (en) * | 2015-02-05 | 2015-07-30 | 주식회사 다림바이오텍 | Manufacturing method of oral formulations using repeated successive dilution and shaking |
-
2006
- 2006-12-26 KR KR1020060133561A patent/KR100827350B1/en not_active IP Right Cessation
Non-Patent Citations (4)
Title |
---|
Korean J. Food Sci. Technol., 31(4), pp. 1057-1064, 1999 |
Korean J. Medicinal Crop Sci. 7(4), pp. 257-262, 1999 |
대한한의학방제학회지 2(1), pp. 97-105, 1991 |
약학회지 43(6), pp. 818-826, 1999 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101216032B1 (en) | 2010-04-29 | 2012-12-31 | 주식회사 미네랄이십일 | Pharmaceutical composition for the treatment and prevention of disease relating diabetes |
KR101540107B1 (en) * | 2015-02-05 | 2015-07-30 | 주식회사 다림바이오텍 | Manufacturing method of oral formulations using repeated successive dilution and shaking |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101160943B1 (en) | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
KR101184666B1 (en) | Composition for improving physiological activity of positive constitution | |
KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR102203657B1 (en) | A composition comprising the complex extract for antiobesity of women | |
KR102112599B1 (en) | Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component | |
KR100827350B1 (en) | Herbal medicine composition for descending blood sugar | |
KR101509796B1 (en) | Composition for preventing or treating obesity comprising blueberry fermentation extract | |
KR100661398B1 (en) | Herbal mixture extract of Pleurotus eryngii, Acanthopanacis Cortex and Notoginseng Radix and composition comprising the same for prevention and treatment of periodontitis | |
KR20190053108A (en) | A composition comprising the complex extract for antiobesity of men | |
KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
KR100637867B1 (en) | Composition comprising Schizandrae Fructus extract for treatment of diabetes | |
KR101456127B1 (en) | A composition for increasing bone growth | |
KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
KR100685472B1 (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome | |
KR20110051545A (en) | Composition for preventing or treating gout comprising mulberry fermentation extract | |
KR100888068B1 (en) | Compositions for suppressing obesity | |
KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
KR101257909B1 (en) | Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
KR20100108869A (en) | Composition containing extract of herbal mixture for prevention or treatment of diabetes | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR20110124444A (en) | Composition for improving physiological activity of cold constitution | |
KR101325825B1 (en) | Composition comprising oenanthe javanica organic acid extract for anti-inflammation | |
KR20110051541A (en) | Composition for preventing or treating gout comprising black galic extract | |
KR100626357B1 (en) | Composition comprising Moutan Radicis Cortex extract for treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130404 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140408 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |